Self-Injection Device – The New D-Flex
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for...
D-Flex® Injection Pen for GLP-1 Medication
Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
Constantly elevated blood sugar levels mean stress for the blood vessels, which can lead to feared complications, including life-threatening sequelae such as a heart attack, organ failure or stroke.
A consistent treatment of Type 2 diabetes as early as possible can significantly improve the quality of life for the patient and the course of the disease.
More About This Company
Haselmeier Acquires Drug Manufacturing Licence and Now Offers Assembly, Labelling Packaging Services
As an innovative, strategic partner company, Haselmeier develops and produces customised, unique systems that are...
Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration
Haselmeier and smart injector monitoring and support solutions company Common Sensing have announced a partnership...
Organisational Changes in Quality Management at Haselmeier
Konrad Betzler was appointed the new chief quality officer (CQO) of the entire Haselmeier Group...